“Discussions” between Bern and the Swiss Pharma, which retains its breath – Rts.ch

“The departments concerned regularly have exchanges with all the economic branches, the Pharma also. Nevertheless, Discussions are planned in the current state. Moreover, ” said the Federal Department of the Interior on Sunday, in response to the announcement by the Sonntagsblick of a “summit” meeting which would be age at the start of the school sector and the Confederation.

During their recent trip to Washington. Furthermore, where they tried in vain to prevent Donald Trump from imposing customs from 39% customs to Swiss exports to the United States, Karin Keller-Sutter and Guy Parmelin had underlined the close contacts between Bern and economic environments. “discussions” between bern swiss pharma, For example, The Chairman of the Board of Directors of Roche Severin Schwan was also part of the senior leaders met across the Atlantic by the President of the Confederation. the Minister of the Economy.

The moment is critical for large Swiss pharmaceutical companies, as the Sonntagsblick and the NZZ AM Sonntag recall. The President threatened them – as well as the other multinationals in the sector – customs duties of up to 250% if they did not lower their prices across the Atlantic. did not make other concessions. An ultimatum was set for them on September 29.

Massive investments in the United States – "discussions" between bern swiss pharma,

In the meantime. the two Swiss Pharma giants invest dozens of billions of dollars in the United States, 23 billion for Novartis and 50 billion for Roche respectively. These developments must in particular allow them to protect themselves from customs barriers.

“The $ 50 billion in investments planned in the “discussions” between bern swiss pharma, United States strengthen our commitment to the health system. patients in this region,” Roche said in a statement in Keystone-ATS on Sunday.

Maintains employment “in the current state”

“In the current state”. the group does not provide that these investments will have an effect on employment in Switzerland and in other countries, he specifies. “We have invested billions of francs in our activities in Switzerland and Europe and we will continue to do so.”

Novartis recently announced to invest $ 23 billion over five years in the United States for the extension of several sites. The giant also wants to create a biomedical research center in San Diego.

Ultimately, the Multinational Rhenish intends to cover all of the American demand with indigenous production.

In an interview with the AWP agency. the CEO of Novartis Vas Narasimhan warned that Europe, at the risk of having supply problems, should further enhance research and innovation in the sector. “discussions” between bern swiss pharma, Additionally, The group wants to maintain production in Switzerland, but expansion is focused on the United States and Asia.

Via his American subsidiary Genentech. Roche is already very present in the United States, where he produces several important drugs, recalls the NZZ AM Sonntag.

The US market, an Eldorado

The direct share of Novartis, Roche and other Swiss manufacturers in the sector represented 5.8% of Swiss GDP in 2022, according to Bak Economics. The branch employs some 50,000 people in Switzerland.

The sector is currently spared by American customs duties. The US market is for him an Eldorado. since prices are free there, and the drugs sold are at much higher prices than in Switzerland and in Europe, a situation that Donald Trump would like to change.

ats/ther